Table 6.
Assessment of studies using the modified Consolidated Standards of Reporting Trials (CONSORT) checklist [39].
| Ref. | 1 | 2a | 2b | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yung et al. [40] | NO | YES | NO | YES | NO | NO | NO | NO | NO | NO | NO | NO | NO | YES | NO |
| Masuda et al. [41] | NO | NO | NO | YES | YES | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO |
| Kawaguchi et al. [42] | NO | YES | YES | YES | NO | NO | NO | NO | NO | NO | NO | YES | YES | NO | NO |
| Tsukada et al. [4] | NO | YES | NO | YES | YES | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO |
| Tsukada et al. [43] | YES | YES | NO | YES | YES | NO | NO | NO | NO | NO | NO | NO | NO | YES | NO |
| Akihiko et al. [44] | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | NO | YES | NO |
Information regarding the following parameters was judged as reported (Yes) or not reported (No): (1) Structured summary of trial design, methods, results, and conclusions; (2a) Scientific background and explanation of rationale; (2b) Specific objectives and/or hypotheses; (3) The intervention for each group, including how and when it was administered, with sufficient detail to enable replication; (4) Completely defined, pre-specified primary and secondary measures of outcome, including how and when they were assessed; (5) How sample size was determined; (6) Method used to generate the random allocation sequence; (7) Mechanism used to implement the random allocation sequence (for example, sequentially numbered containers), describing any steps taken to conceal the sequence until intervention was assigned; (8) Who generated the random allocation sequence, who enrolled teeth; (9) If done, who was blinded after assignment to intervention (for example, care providers, those assessing outcomes), and how and who assigned teeth to intervention; (10) Statistical methods used to compare groups for primary and secondary outcomes; (11) For each primary and secondary outcome, results for each group, and the estimated size of the effect and its precision (for example 95% confidence interval); (12) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses; (13) Sources of funding and other support (for example suppliers of drugs), role of funders; (14) Where the full trial protocol can be accessed, if available.